Alerts will be sent to your verified email
Verify EmailAARTIDRUGS
Aarti Drugs
|
Bliss GVS Pharma
|
Marksans Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
APIs Production Capacity
|
40560.0 MTPA | n/a | n/a |
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
0.52 % | 2.13 % | 1.8 % |
Financials
|
|||
5 yr Average ROE
|
20.52 % | 10.14 % | 17.94 % |
5yr average Equity Multiplier
|
2.24 | 1.36 | 1.39 |
5yr Average Asset Turnover Ratio
|
1.14 | 0.7 | 1.07 |
5yr Avg Net Profit Margin
|
8.19 % | 10.24 % | 12.37 % |
Price to Book
|
3.6 | 1.29 | 4.02 |
P/E
|
26.89 | 16.52 | 23.73 |
5yr Avg Cash Conversion Cycle
|
83.04 Days | 162.62 Days | 68.67 Days |
Inventory Days
|
64.18 Days | 46.41 Days | 88.63 Days |
Days Receivable
|
108.5 Days | 188.89 Days | 72.63 Days |
Days Payable
|
92.79 Days | 68.35 Days | 80.34 Days |
5yr Average Interest Coverage Ratio
|
8.87 | 19.86 | 27.58 |
5yr Avg ROCE
|
23.42 % | 17.11 % | 23.34 % |
5yr Avg Operating Profit Margin
|
14.88 % | 21.12 % | 19.5 % |
5 yr average Debt to Equity
|
0.58 | 0.14 | 0.06 |
5yr CAGR Net Profit
|
13.13 % | -10.55 % | 28.35 % |
5yr Average Return on Assets
|
9.44 % | 7.4 % | 12.96 % |
Shareholdings
|
|||
Promoter Holding
|
57.13 % | 34.97 % | 43.85 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-3.07 % | 1.66 % | -4.4 % |
Change in Mutual Fund Holding (3 Yrs)
|
3.49 % | -0.03 % | 4.14 % |
Aarti Drugs
|
Bliss GVS Pharma
|
Marksans Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|